All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @everariasmd on TikTok · 99s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @everariasmd's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:09It's absolutely insane that there's people out there judging others who are taking GOP medications saying that they're cheating
  2. 0:15When in reality they are clueless when it comes to these medications. They're not doctors
  3. 0:20That's important to understand this information from a healthcare provider. I'm an internal medicine doctor. These medications are life-saving
  4. 0:27These medications for people who are obese people who have
  5. 0:33Corbidities it's important to understand that these medications have shown drastic improvement in weight loss
  6. 0:39But not only that they're not just losing weight. They're also reducing the risk of heart attacks cardiovascular disease hyperlipidemia hyper tension
  7. 0:46Reducing the risk of a stroke basically allowing them to not only lose weight
  8. 0:50But actually live longer as a result of that crazy because we live in a society that when which someone looks at others who are making amazing changes
  9. 0:58Transformation changes really quickly or not as hard quote-unquote. They start judging them when in reality
  10. 1:05Asempic doesn't take away the work
  11. 1:07Asempic is still requires you to actually make sure you're eating healthy make sure you preserve your muscle
  12. 1:14So that's why it's important to talk to nutritionist talk to a doctor so that you're able to work together
  13. 1:18So you're not losing weight too rapidly and you're able to maintain your muscle tissue
  14. 1:22I'm a big advocate for obesity medications because of the data that we have seen so far and this is something that's not going to go away
  15. 1:30So if you are on the edge of whether you should take it or take me these medications or not
  16. 1:34How do you encourage you talk to a medical provider because these medications are literally saving lives?

Doctor's anti-stigma Ozempic message fact-checked

Ever Arias, MD

TikTok creator

37.8K viewsWatch on TikTok

Quick answer

Semaglutide and other GLP-1 receptor agonists have demonstrated statistically significant reductions in major adverse cardiovascular events, body weight, blood pressure, and lipid levels in large randomized controlled trials, most notably SELECT (2023) and the STEP series (2021-2022). The creator accurately reflects the current evidence base when framing these medications as cardiovascular risk-reduction tools, not solely weight loss drugs. However, the emphasis on lifestyle adherence is clinically important: lean mass loss during GLP-1 therapy is documented and mitigated by resistance training and adequate dietary protein, two specifics the video gestures toward without enough precision.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded SemaglutideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Semaglutide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 11 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For Doctor's anti-stigma Ozempic message fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this semaglutide video claims cluster

Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "Doctor's anti-stigma Ozempic message fact-checked" from Ever Arias, MD. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Semaglutide and other GLP-1 receptor agonists have demonstrated statistically significant reductions in major adverse cardiovascular events, body weight, blood pressure, and lipid levels in large randomized controlled trials, most notably SELECT (2023) and the STEP series (2021-2022).

The reason this review is not generic is the source wording and the canonical claim label "glp1 ozempic weightloss associated stigma is only hurting your he." In this clip, the useful excerpt is: "It's absolutely insane that there's people out there judging others who are taking GOP medications saying that they're cheating When in reality they are clueless when it comes to these medications." That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

STEP 1 trial participants regained approximately two-thirds of lost weight within one year of stopping semaglutide (Wilding et al.
People who land here are usually trying to understand whether the Compounded Semaglutide claim is evidence-backed, safe, and relevant to their own situation.
The strongest next step is to compare the claim with FormBlends' Compounded Semaglutide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

Semaglutide and other GLP-1 receptor agonists have demonstrated statistically significant reductions in major adverse cardiovascular events, body weight, blood pressure, and lipid levels in large randomized controlled trials, most notably SELECT (2023) and the STEP series (2021-2022).

FormBlends verdict

Compounded Semaglutide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • Semaglutide and other GLP-1 receptor agonists have demonstrated statistically significant reductions in major adverse cardiovascular events, body weight, blood pressure, and lipid levels in large randomized controlled trials, most notably SELECT (2023) and the STEP series (2021-2022). The creator accurately reflects the current evidence base when framing these medications as cardiovascular risk-reduction tools, not solely weight loss drugs. However, the emphasis on lifestyle adherence is clinically important: lean mass loss during GLP-1 therapy is documented and mitigated by resistance training and adequate dietary protein, two specifics the video gestures toward without enough precision.
  • The SELECT trial (Lincoff et al., 2023, NEJM) showed semaglutide reduced major adverse cardiovascular events by 20% in over 17,000 adults with obesity and established CVD, supporting the cardiovascular benefit claims.
  • STEP 1 trial participants regained approximately two-thirds of lost weight within one year of stopping semaglutide (Wilding et al., 2022, Diabetes, Obesity and Metabolism), meaning these medications typically require long-term use to sustain results.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.

Review Compounded Semaglutide

What You'll Learn

  • The SELECT trial (Lincoff et al., 2023, NEJM) showed semaglutide reduced major adverse cardiovascular events by 20% in over 17,000 adults with obesity and established CVD, supporting the cardiovascular benefit claims.
  • STEP 1 trial participants regained approximately two-thirds of lost weight within one year of stopping semaglutide (Wilding et al., 2022, Diabetes, Obesity and Metabolism), meaning these medications typically require long-term use to sustain results.
  • Lean mass loss during GLP-1 therapy is documented and clinically relevant. Resistance training combined with 1.2 to 1.6 grams of protein per kilogram of body weight daily is associated with better muscle retention during weight loss.
  • Weight stigma is not just socially harmful. Puhl and Heuer (2010, Obesity Reviews) documented that experiencing stigma worsens cardiometabolic health outcomes and reduces engagement with treatment, which directly undermines the goals of GLP-1 therapy.
  • GLP-1 receptor agonists received FDA approval for cardiovascular risk reduction in adults with overweight or obesity in 2024, marking a formal regulatory shift from viewing them as purely weight loss drugs.
  • The evidence base cited in this video applies most strongly to semaglutide 2.4mg (Wegovy) in clinical trial conditions with behavioral support. Real-world outcomes without structured programs tend to be more modest.
  • Talking to a medical provider before starting GLP-1 therapy is not just a legal disclaimer. Monitoring for muscle loss, nutritional adequacy, and cardiovascular markers requires ongoing clinical oversight.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @everariasmd actually say?

The core argument here is that judging GLP-1 users as "cheating" reflects medical ignorance, not moral insight. The creator, an internal medicine physician, says these medications reduce cardiovascular risk, require genuine lifestyle effort, and are "literally saving lives." That is a strong set of claims, and most of them hold up better than you might expect from a 60-second TikTok.

The doctor specifically names heart attacks, stroke, hypertension, and hyperlipidemia as outcomes that improve on GLP-1 therapy. They also push back on the idea that semaglutide is a passive fix, noting users still need to eat well and protect muscle mass. That nuance is worth crediting. Most of this video is medically defensible.

Does the science back this up?

Yes, with some important texture. The cardiovascular data is real and substantial. The SELECT trial (Lincoff et al., 2023, NEJM) followed over 17,000 adults with overweight or obesity and established cardiovascular disease. Semaglutide 2.4mg reduced major adverse cardiovascular events by 20% compared to placebo, with no diabetes diagnosis required. That is the headline finding behind the "saves lives" framing, and it earned FDA approval for cardiovascular risk reduction in 2024.

On metabolic markers, the STEP trials (Wilding et al., 2021, NEJM) showed significant reductions in blood pressure and lipid levels alongside weight loss. The muscle loss concern the creator raises is also backed by evidence. Iepsen et al. (2015, Diabetes Care) and more recent DEXA-based analyses show GLP-1 users can lose meaningful lean mass without resistance training and adequate protein intake, which is why the nutritionist recommendation is not just filler advice.

What did they get wrong (or right)?

Mostly right, but the framing on stigma needs a harder look. The claim that how others view you "should not matter" is motivationally reasonable but clinically incomplete. Research by Puhl and Heuer (2010, Obesity Reviews) documented that weight stigma actually worsens health outcomes, increases cortisol, and reduces treatment engagement. The stigma around GLP-1 medications is a real barrier to care access. So the creator is correct that the judgment is unfounded, but underselling the health impact of stigma itself.

The muscle preservation advice is accurate but underspecified. Saying "make sure you preserve your muscle" without mentioning resistance training or protein targets leaves patients without actionable guidance. Studies suggest 1.2 to 1.6 grams of protein per kilogram of body weight daily is associated with better lean mass retention during GLP-1-assisted weight loss, a detail that would have been useful here.

One word swap matters: the creator says "Asempic" throughout, clearly meaning semaglutide. That is a pronunciation slip, not a factual error, but worth noting in a health context where product names carry regulatory weight.

What should you actually know?

GLP-1 receptor agonists are not a cheat code, and they are not magic. They are a class of medications with a serious and growing evidence base for weight reduction, cardiovascular protection, and metabolic improvement. The SELECT trial data alone should have ended the "cheating" narrative, but cultural bias around body weight runs deeper than clinical data often reaches.

What the video does not tell you is that these medications work best as part of a structured program. The SELECT trial participants had documented cardiovascular disease. The STEP trials used intensive behavioral support alongside drug therapy. Real-world outcomes without that structure tend to be more modest. Stopping the medication also typically leads to weight regain, as shown by Wilding et al. in the STEP 1 extension study (2022, Diabetes, Obesity and Metabolism). This is not a reason to avoid the medication. It is a reason to go in with clear expectations and a provider who will actually monitor your progress.

  • GLP-1s are tools, not substitutes for a clinical relationship.
  • Muscle loss is a real and underreported side effect without proper protein and resistance training.
  • The stigma is medically harmful, not just socially annoying.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Ever Arias, MD · TikTok creator

37.8K views on this video

Ozempic weightloss associated stigma is only hurting your health and how other people view you should not matter!

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about the select trial (lincoff et al., 2023, nejm) showed semaglutide?

The SELECT trial (Lincoff et al., 2023, NEJM) showed semaglutide reduced major adverse cardiovascular events by 20% in over 17,000 adults with obesity and established CVD, supporting the cardiovascular benefit claims.

What does the video say about step 1 trial participants regained approximately two-thirds of lost weight?

STEP 1 trial participants regained approximately two-thirds of lost weight within one year of stopping semaglutide (Wilding et al., 2022, Diabetes, Obesity and Metabolism), meaning these medications typically require long-term use to sustain results.

What does the video say about lean mass loss during glp-1 therapy?

Lean mass loss during GLP-1 therapy is documented and clinically relevant. Resistance training combined with 1.2 to 1.6 grams of protein per kilogram of body weight daily is associated with better muscle retention during weight loss.

What does the video say about weight stigma?

Weight stigma is not just socially harmful. Puhl and Heuer (2010, Obesity Reviews) documented that experiencing stigma worsens cardiometabolic health outcomes and reduces engagement with treatment, which directly undermines the goals of GLP-1 therapy.

What does the video say about glp-1 receptor agonists received fda approval for cardiovascular risk reduction?

GLP-1 receptor agonists received FDA approval for cardiovascular risk reduction in adults with overweight or obesity in 2024, marking a formal regulatory shift from viewing them as purely weight loss drugs.

What does the video say about the evidence base cited in this video applies most strongly?

The evidence base cited in this video applies most strongly to semaglutide 2.4mg (Wegovy) in clinical trial conditions with behavioral support. Real-world outcomes without structured programs tend to be more modest.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Ever Arias, MD, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.